Results 51 to 60 of about 37,026 (217)

Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea

Chronic Diseases and Translational Medicine, EarlyView.
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan   +3 more
wiley   +1 more source

Time Course of Changes in Peripheral Blood Gene Expression During Medication Treatment for Major Depressive Disorder. [PDF]

, 2019
Changes in gene expression (GE) during antidepressant treatment may increase understanding of the action of antidepressant medications and serve as biomarkers of efficacy.
Congdon, Eliza, Cook, Ian A, Coppola, Giovanni, Hamilton, Steven P, Hunter, Aimee M, Krantz, David E, Leuchter, Andrew F   +6 more
core   +1 more source

Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium [PDF]

, 2014
The objective of this study was to assess the cost effectiveness of commonly used antidepressants as first-line treatment of major depressive disorder (MDD) in Belgium.
Annemans, Lieven, Brignone, Mélanie, De Pauw, Ann, Demyttenaere, Koen, Druais, Sylvain, Gauthier, Aline   +5 more
core   +2 more sources

Annual Banned‐Substance Review 18th Edition—Analytical Approaches in Human Sports Drug Testing 2024/2025

Drug Testing and Analysis, EarlyView.
New insights into drug metabolism, distribution, elimination, and detection assays for drugs and methods of sports doping published between 2024 and 2025 are critically reviewed and evaluated in context with the Prohibited List 2025 as established by the World Anti‐Doping Agency.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley   +1 more source

Electroencephalographic and behavioral convulsant effects of hydrobromide and hydrochloride salts of bupropion in conscious rodents

Neuropsychiatric Disease and Treatment, 2009
David C Henshall1, Nick Dürmüller2, H Steve White3, Robert Williams4, Paul Moser2, Mark Dunleavy1, Peter H Silverstone51Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland; 2Porsolt and ...
David C Henshall, Nick Dürmüller, H Steve White, Robert Williams, et al.   +3 more
doaj  

A fatal case of bupropion (Zyban) hepatotoxicity with autoimmune features: Case report

Journal of Medical Case Reports, 2007
Background Bupropion is approved for the treatment of mood disorders and as an adjuvant medication for smoking cessation. Bupropion is generally well tolerated and considered safe.
Humayun Fawwaz, Shehab Thomas M, Tworek Joseph A, Fontana Robert J   +3 more
doaj   +1 more source

Resolution of Levodopa/Dopa‐Decarboxylase Inhibitor—Associated Microscopic Colitis with Subcutaneous Foslevodopa/Foscarbidopa: A Case Series and Review of the Literature

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner, Franziska Eberhardt, Manuela Kofler, Andreas Eigentler, Atbin Djamshidian, Florian Krismer, Anton Hittmair, Heinz Zoller, Valentina Ellinger, Beatrice Heim, Klaus Seppi   +10 more
wiley   +1 more source

Effectiveness of Oral Bupropion and Nortriptyline as an Adjunct Treatment for Reducing the Use of Smokeless Tobacco: A Retrospective Study from a Tobacco Cessation Clinic in a Tertiary Care Hospital in Eastern India

Indian Journal of Public Health
Background: There is supporting evidence on the use of nortriptyline in smoking; however, its effectiveness in smokeless tobacco cessation has not been studied. Objectives: The objectives of this study were to evaluate the effectiveness of oral bupropion
Aparajita Guin, Hoineiting Rebecca Haokip, Sanjib Bandyopadhyay, Saibal Das, Indranil Saha, Aniruddha Basu, Stuti Bhargava   +6 more
doaj   +1 more source

Delayed allergic reaction from bupropion in a 27-year-old male with MDD: A case report and literature review [PDF]

Mental Health Clinician
Introduction Bupropion is an antidepressant approved for the treatment of major depressive disorder (MDD), seasonal affective disorder, and smoking cessation. Nausea, headache, tremor, and insomnia are well-known adverse effects of this medication.
Ana Anghel, BSc(Psych), G. Lucy Wilkening, PharmD   +1 more
doaj   +1 more source

Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the trends in antiobesity medication (AOM) and metabolic and bariatric surgery (MBS) use relative to the 2013 American Medical Association (AMA) declaration of obesity as a chronic disease and semaglutide approval in 2021 in the United States.
Olajide A. Adekunle, Phuc Le, Christopher Boyer, Hamlet Gasoyan, Dev Yash Gupta, Ha T. Tran, Yihua Yue, Michael B. Rothberg   +7 more
wiley   +1 more source